Related Experiment Video
Updated: Mar 20, 2026
08:39
Murine Colitis Modeling using Dextran Sulfate Sodium DSS
Published on: January 19, 2010
51.3K
Grim19 Attenuates DSS Induced Colitis in an Animal Model
Jae-Kyung Kim1,2, Seung Hoon Lee1,2, Seon-Young Lee1,2
1The Rheumatism Research Center, Catholic Research Institute of Medical Science, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul, 137-701, South Korea.
Plos One
|June 4, 2016
Summary
Gene associated with retinoid interferon induced mortality (Grim) 19 reduces severity of DSS induced colitis. Grim19 ameliorates intestinal inflammation by inhibiting STAT3 activation and decreasing proinflammatory cytokine expression.
Area of Science:
- Immunology
- Gastroenterology
- Molecular Biology
Background:
- DSS induced colitis is a chronic inflammatory condition of the gastrointestinal tract with unclear pathogenesis.
- STAT3 signaling pathway is crucial in regulating inflammatory responses and cytokine expression.
- Gene associated with retinoid interferon induced mortality (Grim) 19 is an endogenous inhibitor of STAT3.
Purpose of the Study:
- To investigate the therapeutic potential of Grim19 in DSS induced colitis.
- To elucidate the role of Grim19 in modulating STAT3 activity and intestinal inflammation.
Main Methods:
- Utilized a DSS induced colitis mouse model.
- Administered Grim19 to assess its effects on colitis severity and intestinal tissue protection.
- Analyzed the expression of STAT3, IL-1β, TNF-α, and IL-17 in colon and lymph nodes.
Main Results:
- Grim19 significantly ameliorated DSS induced colitis severity and protected intestinal tissues.
- Grim19 administration led to decreased expression of STAT3, IL-1β, and TNF-α.
- Inhibition of DSS induced colitis progression was observed in Grim19 transgenic mice, associated with reduced STAT3 and IL-17 expression.
Conclusions:
- Grim19 exhibits therapeutic potential in attenuating DSS induced colitis.
- Grim19 acts by suppressing STAT3 activation and reducing the excessive inflammatory response.
- Targeting Grim19 may offer a novel strategy for managing inflammatory bowel diseases.
